Cyberknife treatment for low and intermediate risk prostate cancer

B. Detti, P. Bonomo, L. Masi, R. Doro, S. Cipressi, C. Iermano, I. Bonucci, D. Franceschini, V. Di Cataldo, L. Di Brina, M. Baki, G. Simontacchi, I. Meattini, M. Carini, S. Serni, G. Nicita, L. Livi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Cyberknife is an emerging treatment for early stage prostate cancer. Between October 2012 and January 2014, 32 patients were treated in our institution. Prescribed dose was 35-36.25 Gy in five fractions. Biochemical response was observed in 22 patients. Four patients experienced G2 acute genitourinary toxicity and in two cases we recorded G3 acute GU toxicity. 5 patients experienced G2 acute proctitis. At last follow up visit, all patients were still alive. 29 remained free of disease at last follow up appointment, while three developed a biochemical recurrence. Our experience confirms the efficacy and safety of Cyberknife for localized prostate cancer.

Original languageEnglish
Pages (from-to)188-192
Number of pages5
JournalCancer Investigation
Volume33
Issue number5
DOIs
Publication statusPublished - May 28 2015

Fingerprint

Prostatic Neoplasms
Proctitis
Therapeutics
Appointments and Schedules
Safety
Recurrence

Keywords

  • Cyberknife
  • Prostate cancer
  • Radiation oncology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Detti, B., Bonomo, P., Masi, L., Doro, R., Cipressi, S., Iermano, C., ... Livi, L. (2015). Cyberknife treatment for low and intermediate risk prostate cancer. Cancer Investigation, 33(5), 188-192. https://doi.org/10.3109/07357907.2015.1019679

Cyberknife treatment for low and intermediate risk prostate cancer. / Detti, B.; Bonomo, P.; Masi, L.; Doro, R.; Cipressi, S.; Iermano, C.; Bonucci, I.; Franceschini, D.; Di Cataldo, V.; Di Brina, L.; Baki, M.; Simontacchi, G.; Meattini, I.; Carini, M.; Serni, S.; Nicita, G.; Livi, L.

In: Cancer Investigation, Vol. 33, No. 5, 28.05.2015, p. 188-192.

Research output: Contribution to journalArticle

Detti, B, Bonomo, P, Masi, L, Doro, R, Cipressi, S, Iermano, C, Bonucci, I, Franceschini, D, Di Cataldo, V, Di Brina, L, Baki, M, Simontacchi, G, Meattini, I, Carini, M, Serni, S, Nicita, G & Livi, L 2015, 'Cyberknife treatment for low and intermediate risk prostate cancer', Cancer Investigation, vol. 33, no. 5, pp. 188-192. https://doi.org/10.3109/07357907.2015.1019679
Detti B, Bonomo P, Masi L, Doro R, Cipressi S, Iermano C et al. Cyberknife treatment for low and intermediate risk prostate cancer. Cancer Investigation. 2015 May 28;33(5):188-192. https://doi.org/10.3109/07357907.2015.1019679
Detti, B. ; Bonomo, P. ; Masi, L. ; Doro, R. ; Cipressi, S. ; Iermano, C. ; Bonucci, I. ; Franceschini, D. ; Di Cataldo, V. ; Di Brina, L. ; Baki, M. ; Simontacchi, G. ; Meattini, I. ; Carini, M. ; Serni, S. ; Nicita, G. ; Livi, L. / Cyberknife treatment for low and intermediate risk prostate cancer. In: Cancer Investigation. 2015 ; Vol. 33, No. 5. pp. 188-192.
@article{ef00ae46f5ae48f7bf629e9c795522d4,
title = "Cyberknife treatment for low and intermediate risk prostate cancer",
abstract = "Cyberknife is an emerging treatment for early stage prostate cancer. Between October 2012 and January 2014, 32 patients were treated in our institution. Prescribed dose was 35-36.25 Gy in five fractions. Biochemical response was observed in 22 patients. Four patients experienced G2 acute genitourinary toxicity and in two cases we recorded G3 acute GU toxicity. 5 patients experienced G2 acute proctitis. At last follow up visit, all patients were still alive. 29 remained free of disease at last follow up appointment, while three developed a biochemical recurrence. Our experience confirms the efficacy and safety of Cyberknife for localized prostate cancer.",
keywords = "Cyberknife, Prostate cancer, Radiation oncology",
author = "B. Detti and P. Bonomo and L. Masi and R. Doro and S. Cipressi and C. Iermano and I. Bonucci and D. Franceschini and {Di Cataldo}, V. and {Di Brina}, L. and M. Baki and G. Simontacchi and I. Meattini and M. Carini and S. Serni and G. Nicita and L. Livi",
year = "2015",
month = "5",
day = "28",
doi = "10.3109/07357907.2015.1019679",
language = "English",
volume = "33",
pages = "188--192",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Cyberknife treatment for low and intermediate risk prostate cancer

AU - Detti, B.

AU - Bonomo, P.

AU - Masi, L.

AU - Doro, R.

AU - Cipressi, S.

AU - Iermano, C.

AU - Bonucci, I.

AU - Franceschini, D.

AU - Di Cataldo, V.

AU - Di Brina, L.

AU - Baki, M.

AU - Simontacchi, G.

AU - Meattini, I.

AU - Carini, M.

AU - Serni, S.

AU - Nicita, G.

AU - Livi, L.

PY - 2015/5/28

Y1 - 2015/5/28

N2 - Cyberknife is an emerging treatment for early stage prostate cancer. Between October 2012 and January 2014, 32 patients were treated in our institution. Prescribed dose was 35-36.25 Gy in five fractions. Biochemical response was observed in 22 patients. Four patients experienced G2 acute genitourinary toxicity and in two cases we recorded G3 acute GU toxicity. 5 patients experienced G2 acute proctitis. At last follow up visit, all patients were still alive. 29 remained free of disease at last follow up appointment, while three developed a biochemical recurrence. Our experience confirms the efficacy and safety of Cyberknife for localized prostate cancer.

AB - Cyberknife is an emerging treatment for early stage prostate cancer. Between October 2012 and January 2014, 32 patients were treated in our institution. Prescribed dose was 35-36.25 Gy in five fractions. Biochemical response was observed in 22 patients. Four patients experienced G2 acute genitourinary toxicity and in two cases we recorded G3 acute GU toxicity. 5 patients experienced G2 acute proctitis. At last follow up visit, all patients were still alive. 29 remained free of disease at last follow up appointment, while three developed a biochemical recurrence. Our experience confirms the efficacy and safety of Cyberknife for localized prostate cancer.

KW - Cyberknife

KW - Prostate cancer

KW - Radiation oncology

UR - http://www.scopus.com/inward/record.url?scp=84929928030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929928030&partnerID=8YFLogxK

U2 - 10.3109/07357907.2015.1019679

DO - 10.3109/07357907.2015.1019679

M3 - Article

VL - 33

SP - 188

EP - 192

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 5

ER -